CAMP4 Therapeutics (CAMP) vs Zentalis Pharmaceuticals (ZNTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Zentalis Pharmaceuticals (ZNTL) has outperformed CAMP4 Therapeutics (CAMP) over the past year, gaining 45.9% versus a loss of 0.5%. Zentalis Pharmaceuticals is the larger company by market cap ($259.0 million vs $236.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAMP | ZNTL |
|---|---|---|
| Share price | $3.77 | $2.64 |
| Market cap | $236.58M | $259.04M |
| 1-day change | +1.89% | +5.18% |
| YTD return | -38.50% | +95.56% |
| 1-year return | -0.53% | +45.86% |
| 5-year return | — | -96.48% |
| EPS (TTM) | $-2.32 | $-1.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.75 | $6.95 |
| 52-week low | $2.86 | $1.21 |
| Distance from 52-week high | -51.35% | -62.01% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +180.37% | +177.65% |
| Average volume | 278.11K | 1.21M |
| Shares outstanding | 62.75M | 98.12M |
| Employees | 48 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZNTL has outperformed CAMP by 46.4 percentage points over the past year.
About CAMP4 Therapeutics
CAMP stock →Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Zentalis Pharmaceuticals
ZNTL stock →Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
CAMP vs ZNTL FAQ
Which is bigger, CAMP4 Therapeutics or Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals (ZNTL) is larger, with a market capitalization of $259.04M compared with $236.58M for CAMP4 Therapeutics (CAMP).
Which stock has performed better over the past year, CAMP or ZNTL?
ZNTL returned +45.86% over the past 12 months, compared with -0.53% for CAMP (price return, excluding dividends). Past performance does not predict future results.
Are CAMP4 Therapeutics and Zentalis Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.